clinical trial · NCT03344458
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Growth Hormone Deficiency, PediatricEndocrine System DiseasesHormone DeficiencyPituitary DiseasesTransCon hGH
brief summary
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.
started
Dec 19, 2017
primary completion
Feb 21, 2023
completion
Feb 21, 2023
last updated
May 8, 2024
official title
enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol